Drug Profile
Botulinum toxin B - Supernus Pharmaceuticals
Alternative Names: AN 072; BoNT/B; BotB; Botulinum toxin type B; E 2014; Myobloc; NerBloc; Neurobloc; RimabotulinumtoxinBLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Solstice Neurosciences
- Developer Eisai Co Ltd; Solstice Neurosciences; Supernus Pharmaceuticals; US WorldMeds
- Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
- Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Sialorrhoea; Torticollis
- Phase II/III Muscle spasticity
Most Recent Events
- 16 Nov 2021 Phase-II/III clinical trials in Muscle spasticity (In adults, In the elderly) in Czech Republic (IM) (NCT04815967)
- 16 Nov 2021 Supernus Pharmaceuticals in collaboration with Solstice Neurosciences initiates enrolment in a phase II/III trial in Muscle spasticity (In adults, In the elderly) in USA (IM, Injection) (NCT04815967)
- 27 Oct 2021 Supernus Pharmaceuticals in collaboration with Solstice Neurosciences plans a phase III trial for Sialorrhea(In children, In adolescents) in November 2021 (NCT05097079)